ValuEngine downgraded shares of Genprex (NASDAQ:GNPX) from a buy rating to a hold rating in a research note released on Thursday morning, ValuEngine reports.
Shares of NASDAQ GNPX traded down $0.12 during mid-day trading on Thursday, reaching $1.28. 5,040,162 shares of the company’s stock were exchanged, compared to its average volume of 8,763,254. The firm has a market capitalization of $36.42 million, a price-to-earnings ratio of -1.68 and a beta of 1.28. Genprex has a 52-week low of $0.23 and a 52-week high of $2.26. The company’s 50-day moving average is $0.37 and its 200-day moving average is $0.65.
Genprex (NASDAQ:GNPX) last released its quarterly earnings results on Thursday, November 14th. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07.
A hedge fund recently bought a new stake in Genprex stock. Citadel Advisors LLC purchased a new position in shares of Genprex Inc (NASDAQ:GNPX) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 31,529 shares of the company’s stock, valued at approximately $39,000. Citadel Advisors LLC owned 0.20% of Genprex at the end of the most recent quarter. Hedge funds and other institutional investors own 10.38% of the company’s stock.
Genprex, Inc operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells.
Featured Story: How Investors Can Profit from Options Trading
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.